Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
| |
Ícono de BMS, estudio Activo, no reclutando

Activo, no reclutando

ID del estudio CA209-9GY  |   NCT03455452

An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer

Ícono de advertencia
Lo sentimos, este estudio ya no acepta nuevos participantes, pero aún está en curso.
Puede hacer clic en el botón “Verificar su Elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad
Comuníquese con nosotros si necesita ayuda
855-907-3286

Resumen

  • Ícono de género masculino y femenino
  • 18+
  • Ícono de BMS, estudio Activo, no reclutando
    Activo, no reclutando

Descripción general

This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with renal cell carcinoma, who start a new systemic therapy with nivolumab for the first time and within the market authorization approval, following a first or second-line therapy.

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Inclusion Criteria: - Adult patients with the diagnosis of advanced RCC (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab as second or third line therapy for the first time for the treatment of RCC, according to the label approved in France Exclusion Criteria: - Patients with a primary diagnosis of a cancer other than advanced RCC within the past five years, ie, a cancer other than RCC that requires systemic or other treatment - Patients previously treated with anti-PD1, anti-PDL1 or anti-CTLA4 therapy - Patients currently included in an interventional clinical trial for their advanced or RCC. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for OS can be enrolled Other protocol defined inclusion/exclusion criteria could apply

Opciones de tratamiento

Brazos del estudio

INTERVENCIÓN ASIGNADA

Brazos del estudio

Cohort 2: Nivolumab + Ipilimumab

INTERVENCIÓN ASIGNADA

Brazos del estudio

Renal Cell Carcinoma (RCC) Participants

INTERVENCIÓN ASIGNADA

Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias